C4 Therapeutics, Inc. (NASDAQ:CCCC) Position Raised by Geode Capital Management LLC

Geode Capital Management LLC lifted its position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) by 0.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,369,676 shares of the company’s stock after acquiring an additional 7,460 shares during the period. Geode Capital Management LLC owned 1.94% of C4 Therapeutics worth $7,809,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of CCCC. Headlands Technologies LLC acquired a new position in C4 Therapeutics during the 2nd quarter valued at about $45,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of C4 Therapeutics during the second quarter valued at approximately $51,000. Point72 DIFC Ltd acquired a new position in shares of C4 Therapeutics during the third quarter worth approximately $51,000. Cynosure Group LLC bought a new position in C4 Therapeutics in the 3rd quarter worth approximately $57,000. Finally, Aigen Investment Management LP acquired a new stake in C4 Therapeutics in the 3rd quarter valued at approximately $82,000. Institutional investors and hedge funds own 78.81% of the company’s stock.

Analyst Ratings Changes

CCCC has been the subject of a number of analyst reports. Wells Fargo & Company upgraded C4 Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $8.00 to $12.00 in a research report on Thursday, December 19th. Stephens began coverage on shares of C4 Therapeutics in a report on Monday, November 18th. They issued an “equal weight” rating and a $4.00 price objective for the company. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, C4 Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.67.

C4 Therapeutics Trading Up 1.7 %

Shares of NASDAQ CCCC opened at $3.66 on Friday. C4 Therapeutics, Inc. has a twelve month low of $3.43 and a twelve month high of $11.88. The firm has a 50-day moving average of $4.64 and a two-hundred day moving average of $5.39. The company has a market capitalization of $258.36 million, a price-to-earnings ratio of -2.15 and a beta of 2.92.

C4 Therapeutics (NASDAQ:CCCC) last released its earnings results on Thursday, October 31st. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.05. The business had revenue of $15.36 million during the quarter, compared to analyst estimates of $5.95 million. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%. As a group, research analysts predict that C4 Therapeutics, Inc. will post -1.52 earnings per share for the current year.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.